Literature DB >> 22497524

Advances in zebrafish high content and high throughput technologies.

Filip Miscevic1, Ori Rotstein, Xiao-Yan Wen.   

Abstract

The zebrafish has emerged as an excellent transitional screening model system between cell-based assays, which are rapid and inexpensive but have limited physiological relevance, and higher vertebrate models, which have better physiological relevance, but are more time-consuming and expensive to deploy. As vertebrates, zebrafish maintain significant evolutionary proximity to humans and have been validated as robust models for drug research, studies of mechanism and behavioral genetics. Unlike higher vertebrate models, zebrafish are well-suited to high-throughput applications owing to their high fecundity, rapid extrauterine development and transparency during organogenesis enabling in vivo labeling and imaging. Recent advances have been made in automating high content and high-throughput zebrafish screens, with the goal of developing fully automated drug screening platforms. The application and continued development of these technologies holds potential clinical significance in drug discovery and elucidating disease mechanisms.

Entities:  

Mesh:

Year:  2012        PMID: 22497524     DOI: 10.2174/138620712801619140

Source DB:  PubMed          Journal:  Comb Chem High Throughput Screen        ISSN: 1386-2073            Impact factor:   1.339


  12 in total

1.  Do Zebrafish Obey Lipinski Rules?

Authors:  Keith Long; Stephen J Kostman; Christian Fernandez; James C Burnett; Donna M Huryn
Journal:  ACS Med Chem Lett       Date:  2019-04-24       Impact factor: 4.345

Review 2.  Regulatory pathways affecting vascular stabilization via VE-cadherin dynamics: insights from zebrafish (Danio rerio).

Authors:  Shahram Eisa-Beygi; R Loch Macdonald; Xiao-Yan Wen
Journal:  J Cereb Blood Flow Metab       Date:  2014-07-16       Impact factor: 6.200

3.  Development of a zebrafish sepsis model for high-throughput drug discovery.

Authors:  Anju Mary Philip; Youdong Wang; Antonio Mauro; Suzan El-Rass; John C Marshall; Warren L Lee; Arthur S Slutsky; Claudia C dosSantos; Xiao-Yan Wen
Journal:  Mol Med       Date:  2017-06-07       Impact factor: 6.354

4.  Fluorescent Reporter Zebrafish Line for Estrogenic Compound Screening Generated Using a CRISPR/Cas9-Mediated Knock-in System.

Authors:  Ahmed Abdelmoneim; Cedric L Clark; Motoko Mukai
Journal:  Toxicol Sci       Date:  2020-02-01       Impact factor: 4.849

5.  Pro-angiogenic activity of notoginsenoside R1 in human umbilical vein endothelial cells in vitro and in a chemical-induced blood vessel loss model of zebrafish in vivo.

Authors:  Bin-Rui Yang; Si-Jia Hong; Simon Ming-Yuen Lee; Wei-Hong Cong; Jian-Bo Wan; Zhe-Rui Zhang; Qing-Wen Zhang; Yi Zhang; Yi-Tao Wang; Zhi-Xiu Lin
Journal:  Chin J Integr Med       Date:  2014-12-22       Impact factor: 1.978

6.  Zebrafish Entrapment By Restriction Array (ZEBRA) device: a low-cost, agarose-free zebrafish mounting technique for automated imaging.

Authors:  Lauren L Bischel; Brianah R Mader; Julie M Green; Anna Huttenlocher; David J Beebe
Journal:  Lab Chip       Date:  2013-05-07       Impact factor: 6.799

7.  Network pharmacology: a new approach for chinese herbal medicine research.

Authors:  Gui-Biao Zhang; Qing-Ya Li; Qi-Long Chen; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-20       Impact factor: 2.629

8.  Commentary: Establishing zebrafish as a model to study the anxiolytic effects of scopolamine.

Authors:  Murilo S de Abreu; Ashton J Friend; Tamara G Amstislavskaya; Allan V Kalueff
Journal:  Front Pharmacol       Date:  2018-04-03       Impact factor: 5.810

9.  Zebrafish as a Model for the Study of Live in vivo Processive Transport in Neurons.

Authors:  Valérie Bercier; Marion Rosello; Filippo Del Bene; Céline Revenu
Journal:  Front Cell Dev Biol       Date:  2019-02-19

Review 10.  Preclinical Models for Investigation of Herbal Medicines in Liver Diseases: Update and Perspective.

Authors:  Hor-Yue Tan; Serban San-Marina; Ning Wang; Ming Hong; Sha Li; Lei Li; Fan Cheung; Xiao-Yan Wen; Yibin Feng
Journal:  Evid Based Complement Alternat Med       Date:  2016-01-28       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.